{"id":"azd8871","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Neutropenia"},{"rate":"20-30%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL4297483","moleculeType":"Small molecule","molecularWeight":"742.92"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD8871 works by selectively inhibiting the PI3K delta enzyme, which plays a key role in the activation of immune cells. This inhibition can help to reduce inflammation and modulate the immune response. By targeting PI3K delta, AZD8871 aims to provide a therapeutic benefit in various diseases.","oneSentence":"AZD8871 is a small molecule that targets the PI3K delta inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:25.594Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL)"}]},"trialDetails":[{"nctId":"NCT03645434","phase":"PHASE2","title":"A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-10-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":73},{"nctId":"NCT02971293","phase":"PHASE2","title":"Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-12-15","conditions":"Chronic Obstructive Pulmonary Disease COPD","enrollment":42},{"nctId":"NCT02814656","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT03159442","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-06-19","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD8871","genericName":"AZD8871","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD8871 is a small molecule that targets the PI3K delta inhibitor. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}